Impact of thymalin on the values of cells, humoral immunity and the life quality in elderly patients with COVID-19

DOI: https://doi.org/10.29296/25877305-2021-06-09
Download full text PDF
Issue: 
6
Year: 
2021

Professor V. Khavinson(1, 2), Corresponding Member of RAS, MD; Professor B. Kuznik(3), MD;
Professor S. Rukavishnikova(4, 5), Doctor of Biological Sciences; Professor S. Trofimova(1, 6), MD;
Associate Professor N. Linkova(1, 6, 7), Doctor of Biological Sciences; Associate Professor T. Akhmedov(4,
5), Candidate of Medical Sciences; V. Bashuk(7), MD (1)Saint Petersburg Institute of Bioregulation and
Gerontology (2)Pavlov Institute of Physiology of the Russian Academy of Sciences (3)Chita State Medical
Academy (4)Saint Petersburg City Multiprofile hospital Second (5)Pavlov First Saint Petersburg State Medical
University (6)Academy of Postgraduate Education, Federal Research and Clinical Center for Specialized Types
of Medical Care and Medical Technologies, Federal Biomedical Agency of Russia, Moscow (7)Belgorod National
Research University

Often elderly people have severe course of COVID-19 and fast decreasing antibody concentration IgG to SARS-CoV-2. The severe course of COVID-19 may lead to decrease of the life quality and social maladjustment of older age parsons. Thymalin is the immunomodulatory peptide drug with physiological mechanism of activity. The goal of the investigation is to estimate the thymalin influence on the immunogram indicators and antibody IgG к SARS-CoV-2 concentration in elderly patients with COVID-19 on 200th day after treatment. Methods. The control group includes 50 elderly patients with COVID-19 on the standard treatment. The base group consists of 38 elderly patients with COVID-19 on the standard treatment with thymalin applying. Results. It was shown the decreasing of IL-6 blood concentration in 5.95 times to norm level and increasing the number of lymphocytes, CD3+, СD4+ cells in 2.15, 1.95 and 3.73 times to norm level after the standard treatment with thymalin applying in elderly patients with COVID-19 on the 200th day after treatment. The standard therapy has no the same effects. The level of IgG antibody to SARS-CoV-2 on the 200th day after the thymalin applying in addition to the standard treatment was in 4.25 times higher in comparison with this parameter in standard therapy group. Conclusion. The thymalin applying in addition to the standard treatment in elderly patients with COVID-19 normalizes immunogram indicators and prolongs during 200 days the safety high antibody concentration of IgG to SARS-CoV-2, which prevent reinfection. At the same time antibody level of IgG to SARS-CoV-2 in the standard treatment group practically disappeared to the 200th days after hospitalization.
Keywords: 
therapy
infectious diseases
thymalin
COVID-19
antibody concentration of IgG to SARS-CoV-2
elderly patients

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Chen Y., Klein S.L., Garibaldi B.T. et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021; 65: 101205. DOI: 10.1016/j.arr.2020.101205
  2. Nikolich-Zugich J., Knox K.S., Rios C.T. et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020; 42 (2): 505–14. DOI: 10.1007/s11357-020-00186-0
  3. Soiza R.L., Scicluna C., Thomson E.C. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021; 50 (2): 279–83. DOI: 10.1093/ageing/afaa274
  4. Garrigues E., Janvier P., Kherabi Y. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81 (6): e4–e6. DOI: 10.1016/j.jinf.2020.08.029
  5. Buselli R., Corsi M., Baldanzi S. et al. Professional quality of life and mental health outcomes among health care workers exposed to SARS-CoV-2 (COVID-19). Int J Environ Res Public Health. 2020; 17 (17): 6180. DOI: 10.3390/ijerph17176180
  6. Havinson V.H. Lekarstvennye peptidnye preparaty: proshloe, nastojaschee, buduschee. Klinicheskaja meditsina. 2020; 98 (3): 165–77 [Khavinson V.Kh. Khavinson V.K. Peptide medicines: past, present, future. Clinical Medicine (Russian Journal). 2020; 98 (3): 165–77 (in Russ.)]. DOI: 10.30629/0023-2149-2020-98-3-165-177
  7. Hohlov D.T., Degtjarev A.A., Zaharov V.E. i dr. Profilakticheskaja effektivnost' timalina v sochetanii s vaktsinnymi preparatami. Voenno-meditsinskij zhurnal im. N.I. Pirogova. 1987; 37–9 [Chochlov D.T., Degtjarev A.A., Zakharov V.E. et al. Thymalin prophylactic efficiency in combination of vassine-based drugs. Military-Medical Journal named after N.I. Pirogov. 1987; 37–9 (in Russ.)].
  8. Kolchina N., Khavinson V., Linkova N. et al. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research. 2019; 47 (20): 10553–63. DOI: 10.1093/nar/gkz850
  9. Khavinson V.Kh., Linkova N.S., Kvetnoy I.M. et al. Thymalin: activation of differentiation of human hematopoietic stem cells. Bull Exp Biol Med. 2020; 170 (1): 118–22. DOI: 10.1007/s10517-020-05016-z
  10. Khavinson V., Linkova N., Dyatlova A. et al. Peptides: prospects for use in the treatment of COVID-19. Molecules. Special Issue «Peptide Therapeutics 2.0». 2020; 25 (10): 4389. DOI: 10.3390/molecules25194389
  11. Havinson V.H., Lin'kova N.S., Chalisova N.I. i dr. Timalin: primenenie dlja immunokorrektsii i molekuljarnye aspekty biologicheskoj aktivnosti. Uspehi sovremennoj biologii. 2021; 141 (1): 25–31 [Khavinson V.Kh., Linkova N.S., Shalisova N.I. et al. Thymalin: Application for Immunocorrection and Molecular Aspects of Biological Activity. Uspekhi sovremennoi biologii. 2021; 141 (1): 25–31 (in Russ.)]. DOI: 10.31857/S0042132420060046
  12. Kozlov V.A., Savchenko A.A., Kudrjavtsev I.V. i dr. Klinicheskaja immunologija. Krasnojarsk: Polikor, 2020; 386 s. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Klinicheskaya immunologiya. Krasnoyarsk: Polikor, 2020; 386 s. [(in Russ.)]. DOI: 10.17513/np.438 (in Russ.)]. DOI: 10.17513/np.438
  13. Kuznik B.I., Havinson V.H., Lin'kova N.S. COVID-19: vlijanie na immunitet, sistemu gemostaza i vozmozhnye puti korrektsii. Uspehi fiziologicheskih nauk. 2020; 51 (4): 51–63 [Kuznik B.I., Khavinson V.Kh., Linkova N.S. COVID-19: Impact on Immunity, Hemostasis and Possible Methods of Correction. Uspekhi fiziologicheskikh nauk. 2020; 51 (4): 51–63 (in Russ.)]. DOI: 10.31857/S0301179820040037
  14. Havinson V.H., Kuznik B.I., Volchkov V.A. i dr. Vlijanie timalina na adaptivnyj immunitet pri provedenii kompleksnoj terapii patsientov s COVID-19. Klinicheskaja meditsina. 2020; 98 (8): 593–9 [Khavinson V.K., Kuznik B.I., Volchkov V.A. et al. Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19. Clinical Medicine (Russian Journal). 2020; 98 (8): 593–9 (in Russ.)]. DOI: 10.30629/0023-2149-2020-98-8-593-599
  15. Khavinson V.Kh., Kuznik B.I., Trofimova S.V. et al. Results and prospects of using of activator of hematopoietic stem cell differentiation in complex therapy of patients with COVID-19. Stem Cells Review and Reports. Special Issue on COVID-19 Pandemic and Stem Cells. 2021. DOI: 10.1007/s12015-020-100-87-6.
  16. Theel E.S., Harring J., Hilgart H. et al. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin Microbiol. 2020; 58 (8): e01243–20. DOI: 10.1128/JCM.01243-20
  17. Mamaev A.N., Kudlaj D.A. Statisticheskie metody v meditsine. M.: Prakticheskaja meditsina, 2021; 136 s. [Mamaev A.N., Kudlay D.A. Statisticheskie metody v meditsine. M.: Prakticheskaya meditsina, 2021; 136 s. (in Russ.)].
  18. Gubernatorova E.O., Gorshkova E.A., Polinova A.I. et al. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53: 13–24. DOI: 10.1016/j.cytogfr.2020.05.009